Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Interest Expenses (2016 - 2019)

Vistagen Therapeutics (VTGN) has disclosed Interest Expenses for 8 consecutive years, with -$1500.0 as the latest value for Q4 2019.

  • Quarterly Interest Expenses fell 183.33% to -$1500.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was -$1500.0 through Sep 2020, up 85.98% year-over-year, with the annual reading at $8000.0 for FY2019, 10.11% down from the prior year.
  • Interest Expenses hit -$1500.0 in Q4 2019 for Vistagen Therapeutics, up from -$15400.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $755000.0 in Q2 2015 to a low of -$15400.0 in Q3 2019.
  • Historically, Interest Expenses has averaged $45576.5 across 5 years, with a median of $2000.0 in 2016.
  • Biggest five-year swings in Interest Expenses: skyrocketed 200.0% in 2017 and later plummeted 631.03% in 2019.
  • Year by year, Interest Expenses stood at $3000.0 in 2015, then plummeted by 66.67% to $1000.0 in 2016, then surged by 100.0% to $2000.0 in 2017, then decreased by 10.0% to $1800.0 in 2018, then crashed by 183.33% to -$1500.0 in 2019.
  • Business Quant data shows Interest Expenses for VTGN at -$1500.0 in Q4 2019, -$15400.0 in Q3 2019, and $1800.0 in Q4 2018.